ANZ HY Profit Rises

By RTTNews Staff Writer ✉ | Published: 5/3/2022 9:21 PM ET

Australia And New Zealand Banking Group Ltd. (ANZ.AX,ANZBY.PK,ANZ) reported a profit attributable to shareholders of the company for the half year ended 31 March 2022 of A$3.53 billion or 117.7 cents per share up from A$2.94 billion or 98.4 cents per share in the previous year.

Cash profit for the period grew to A$3.11 billion from A$2.98 billion last year.

Operating income was A$9.54 billion up from A$8.37 billion in the previous year.

Net interest income grew to A$7.10 billion from A$6.99 billion in the prior year.

ANZ's Common Equity Tier 1 Ratio was strong at 11.5% and Cash Return on Equity was 10%. The proposed Interim Dividend is 72 cents per share, fully franked.

For comments and feedback contact: editorial@rttnews.com

Business News

Biotech Stocks Facing FDA Decision In March 2023

Biotech Stocks Facing FDA Decision In February 2023

Biotech stocks Facing FDA Decision in January 2023

Editors Pick

United Airlines, Archer To Launch First Air Taxi Route In Chicago

United Airlines and Archer Aviation Inc. announced plans to launch the first commercial electric air taxi route in Chicago, between O'Hare International Airport or ORD and Vertiport Chicago. As part of their urban air mobility or UAM network buildout, both companies will utilize Archer's electric vertical takeoff and landing or eVTOL aircraft in the new route.

Aunt Millie's Our Family White Hot Dog Buns Recalled

Fort Wayne, Indiana-based Perfection Bakeries D/B/A Aunt Millie's is recalling 8 ct. packages of Our Family White Hot Dog Buns citing the possible presence of undeclared sesame, a known allergen, the U.S. Food and Drug Administration said. The product comes in a printed plastic package marked with "Our Family Hot Dog Buns 8 ct." on the top and has a blue twist tie.

Ascend Labs Recalls Oral Anticoagulant Dabigatran Etexilate Capsules

Parsippany, New Jersey -based Ascend Laboratories LLC. is recalling Dabigatran Etcxilate capsules citing the detection of N-Nitrosodimethylamine or NDMA impurity, a probable human carcinogen, the U.S. Food and Drug Administration said. The product is used as an oral anticoagulant to lower the risk of stroke and blood clots.